Cardinal Health, Inc. Q4 2026 Earnings Call Summary
Cardinal Health’s fiscal 2026 performance was supported by resilient demand in Pharmaceutical and Specialty Solutions, with Specialty strength growing over 25% and a $100 million net nonrecurring GMPD tailwind from IEEPA tariff refunds. For fiscal 2027, it guided EPS of $12.40 to $12.60, with GMPD profit $200 million to $220 million, plus $700 million CapEx and at least $1 billion share repurchases.
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed EPS range ($12.40 to $12.60), GMPD profit range ($200M to $220M), and the stated CapEx ($700M) plus share repurchase authorization (new $5B, with at least $1B planned). The guidance also explicitly ties revenue headwinds to IRA price changes and flags Iran conflict as a potential downside to GMPD results.
Market read
Fresh guidance ranges, capital allocation, and explicit tariff/IRA/geopolitical assumptions can drive repricing of CAH’s forward earnings and risk premium.
What to watch
The call emphasizes capacity bottleneck investments (refrigeration/freezing) and integration/synergy timing; execution delays could matter as much as macro assumptions for Specialty and ‘Other’ profit growth.
Background
The piece summarizes Cardinal Health’s fiscal 2026 performance drivers and provides fiscal 2027 outlook, segment assumptions, and capital allocation plans discussed on its Q4 2026 earnings call.
Ticker impact
Cardinal Health guided fiscal 2027 EPS to $12.40 to $12.60 and outlined GMPD profit $200M to $220M assumptions.
Near-term bias modestly positive if investors view the EPS range and buyback authorization as credible despite tariff and geopolitical uncertainties.
The article discloses specific 2027 EPS and segment profit ranges plus CapEx and share repurchase authorization, which can re-anchor valuation expectations; however, it also flags Iran-related downside risk and IRA revenue headwinds.
Market effects
Highlights how distributors are modeling IRA pricing impacts and tariff offsets, which can influence read-across expectations for peers’ margins.
Iran conflict risk is framed as a potential margin pressure channel for US healthcare logistics supply chains.
Tariff refund tailwinds and geopolitical supply-chain costs reinforce sensitivity of global medical distribution economics to policy and conflict.
Counterpoint
The guidance relies on a modest tariff tailwind and assumes no adverse profit impact from IRA pricing, so any deviation in policy or fuel/commodity costs could quickly pressure margins.
Key entities
- companyCardinal Health, Inc.
US healthcare distributor providing fiscal 2027 EPS and segment profit guidance, plus capital allocation and risk assumptions.
- acquisition/integrationAdvanced Diabetes Supply (ADS)
Integration progress described as ahead of schedule with synergies exceeding initial expectations.
- acquisitionStrive Medical
Recently completed acquisition expected to add profit growth to the ‘Other’ segment.
- acquisitionAdaptHealth
Pending diabetes acquisition expected to add profit growth to the ‘Other’ segment.
